Welcome to our dedicated page for Elanco Animal Health news (Ticker: ELAN), a resource for investors and traders seeking the latest updates and insights on Elanco Animal Health stock.
Elanco Animal Health Incorporated (NYSE: ELAN) is a global animal health company focused on products and services that prevent and treat disease in farm animals and pets. The ELAN news feed on Stock Titan aggregates company announcements, regulatory updates and other disclosures so readers can follow how Elanco’s strategy and product portfolio evolve over time.
Elanco regularly issues news on pet health innovations, including prescription products for dogs and cats. Recent press releases have covered developments in canine dermatology, such as Zenrelia tablets for control of itching and inflammation associated with skin allergies in dogs and Befrena, an injectable monoclonal antibody targeting canine allergic and atopic dermatitis. The company also reports on its Credelio and Credelio Quattro brands for parasite control in dogs and Credelio CAT for cats, including label expansions, emergency use authorizations and new indications such as protection related to Lyme disease and emerging tick species.
Investors and industry followers will also find farm animal and corporate updates, including quarterly financial results, guidance, restructuring plans and productivity initiatives like Elanco Ascend. News items describe trends in pet health and farm animal revenue, progress in innovation pipelines, changes to manufacturing and R&D footprints, and participation in major healthcare and investor conferences.
This ELAN news page helps readers track how Elanco’s innovation, portfolio and productivity strategy is reflected in product approvals, regulatory milestones, financial performance and strategic partnerships. For anyone monitoring animal health markets, veterinary therapeutics or ELAN stock, it provides a centralized view of the company’s most recent public communications.
Elanco Animal Health reported Q4 2022 revenue of $988 million, an 11% decline year-over-year, with a net loss of $54 million. For the full year, total revenue was $4,418 million, down 7% from 2021. Adjusted net income for Q4 was $95 million, with an adjusted EBITDA margin of 17.6%. The company has guided for 2023 revenues between $4,280 million and $4,400 million and a reported net loss of $157 million to $109 million. Elanco is pursuing FDA approvals for new products expected in early 2024. The company faces ongoing competitive pressures but anticipates sales growth from innovation and pricing.
Elanco Animal Health (NYSE: ELAN) announced the appointment of Tim Bettington as the executive vice president of Corporate Strategy and Market Development, effective March 20. Bettington's role will focus on corporate strategy and market development, particularly in preparing for a significant innovation period and driving growth initiatives for 2025 and beyond. He brings over 25 years of experience in animal health, previously serving at Zoetis and Boehringer Ingelheim. CEO Jeff Simmons emphasized the addition strengthens Elanco's leadership, aimed at enhancing market share and executing successful product launches amidst an exciting pipeline.
Elanco Animal Health Incorporated (NYSE: ELAN) will release its fourth quarter and full year 2022 financial results on February 21, 2023. A conference call is scheduled for 8:00 a.m. eastern time that day, where the company will discuss its performance with investors and media. The call will be accessible via a live webcast posted on Elanco's website, with a replay available shortly after. Elanco is committed to providing innovative animal health products and services aimed at improving the health of farm animals and pets, with nearly 70 years of experience in the field.
Elanco Animal Health (NYSE: ELAN) will participate in the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 12:45 p.m. ET. The company will be represented by Jeff Simmons, president and CEO, who will address analyst questions during the event.
A live audio webcast will be accessible in the 'Events and Presentations' section of Elanco’s investor website, with a replay available for 30 days.
Elanco Animal Health (NYSE:ELAN) announces FDA approval for Bexacat™ (bexagliflozin tablets), the first oral medication improving glycemic control in diabetic cats. Approximately 600,000 cats in the U.S. are diagnosed with diabetes, with 125,000 untreated due to insulin's complexities. Bexacat offers a non-insulin, once-daily treatment, enhancing convenience for pet owners. In pivotal studies, 83% of treated cats showed improvement by day 56. Bexacat is expected to be available by Q1 2023, enriching Elanco's feline health portfolio alongside other innovative products.
Elanco Animal Health (NYSE: ELAN) announced its participation in the Evercore ISI 5th Annual HealthCONx Conference on November 29, 2022. CEO Jeff Simmons will engage in a fireside chat at 8:50 a.m. Eastern time. A live audio webcast will be accessible via the company’s investor website, with a replay available for 90 days post-event. Elanco, a leader in animal health for nearly 70 years, focuses on innovative solutions for farm animals and pets, committed to enhancing animal health and community impact.
Elanco Animal Health reported Q3 2022 results with revenues of $1,028 million, a 9% decline from last year. Despite challenges, adjusted EPS rose 5% to $0.20. A net loss of $49 million was recorded, improving from $104 million in Q3 2021. The company updated its full-year guidance, forecasting revenue between $4,385 million and $4,430 million. Significant foreign exchange impacts are anticipated, with a loss of around $225 million. Elanco expects five blockbuster product approvals by mid-2024, including a parasiticide and a monoclonal antibody for canine parvovirus.
Elanco Animal Health Incorporated (NYSE: ELAN) will publish its third quarter 2022 financial results on November 8, 2022. Following this, a conference call with investors and media is scheduled for 8:00 a.m. ET to discuss the company’s performance in detail. Participants can access the live webcast through the company's investor relations website. Elanco aims to innovate and deliver products for animal health, enhancing the welfare of animals and providing value across the animal health ecosystem.
Elanco Animal Health (NYSE: ELAN) announced that Scott Ferguson is stepping down from its Board of Directors to focus on other commitments with Sachem Head Capital Management. Ferguson expressed confidence in Elanco's strategy, emphasizing its path to creating shareholder value through cost discipline and innovation. R. David Hoover, chairman of the board, acknowledged Ferguson's contributions during his tenure since December 2020. Jeffrey N. Simmons, CEO, reaffirmed strong strategy execution, promising upcoming innovations that aim to enhance value for customers and shareholders.
Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022. Jeff Simmons, the president and CEO, is scheduled for a fireside chat at 2:50 p.m. Eastern time.
A live audio webcast of the event will be accessible via the company’s investor website, with a replay available for 90 days.